VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
Completed · Phase 1
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of VNP40101M in treating young patients with recurrent, progressive, or refractory primary brain tumors.
Key facts
- Study ID
- NCT00098761
- Run by
- Pediatric Brain Tumor Consortium
- People needed
- 42
- Starts
- 2005-02-01
- Expected to finish
- 2008-02-01
- Last updated by the study team
- 2011-06-30
Who can join
Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCSF Comprehensive Cancer Center — San Francisco, California, United States
- Children's National Medical Center — Washington D.C., District of Columbia, United States
- Children's Memorial Hospital - Chicago — Chicago, Illinois, United States
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States
- St. Jude Children's Research Hospital — Memphis, Tennessee, United States
- Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital — Houston, Texas, United States
- Children's Hospital and Regional Medical Center - Seattle — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.